Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/14/2007

Keflex Product Sales Total $3.1 Million in Quarter; Amoxicillin PULSYS NDA

Review Ongoing - PDUFA Date in January 2008

GERMANTOWN, Md., Nov. 14 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced financial and operational results for the quarter ended September 30, 2007.

MiddleBrook reported third quarter 2007 revenue of $3.1 million, up from revenue of $2.7 million in the second quarter of 2007 and from $2.4 million in the third quarter of 2006. Revenue for the first nine months of 2007 increased to $7.6 million, from revenue of $3.6 million for the first nine months of 2006.

MiddleBrook reported research and development (R&D) expenses in the third quarter of $5.5 million, compared to second quarter 2007 R&D expenses of $5.4 million and third quarter 2006 R&D expenses of $5.7 million. Total expenses for the third quarter of 2007 were $13.2 million, compared to $12.2 million in the second quarter of 2007 and $12.2 million in the third quarter of 2006.

Net loss was $10.1 million for the third quarter, compared to a net loss of $9.5 million in the second quarter of 2007 and a net loss of $9.9 million in the third quarter of 2006. Net loss for the first nine months of 2007 was $33.2 million, compared to a net loss of $28.2 million in the first nine months of the prior year.

Net loss per share applicable to common stockholders during the third quarter of 2007 was ($0.22), compared to a net loss per share of ($0.21) in the prior quarter, and a net loss per share of ($0.33) in the comparable quarter of last year. Net loss per share applicable
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... By Dennis Thompson ... -- A new experimental drug has saved a group of ... of Ebola virus that kills up to 90 percent of ... monkeys infected with lethal doses of Marburg virus, even when ... study published Aug. 20 in the journal Science Translational ...
(Date:8/20/2014)... Bottom Line: Less than 42 percent of women ... and the factors associated with foregoing reconstruction included ... being older. , Author: Monica Morrow, M.D., of ... and colleagues. , Background: The Women,s Health and ... for breast reconstruction following a mastectomy. Still, most ...
(Date:8/20/2014)... study of chronic users of codeine-containing cough syrups ... brain white matter and associates these changes with ... used diffusuion tensor imaging (DTI) (an MR imaging ... white matter integrity of chronic CCS users. Deficits ... including the inferior fronto-occipital fasciculus, which other studies ...
(Date:8/20/2014)... August 20, 2014 Hundreds of Mirena ... of women who were allegedly injured due to spontaneous ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard LLP ... August 15, 2014, the Court has established procedures regarding ... lawsuits that are part of the proceeding’s initial disposition ...
(Date:8/20/2014)... Gray HealthDay Reporter WEDNESDAY, ... rare, colds, flu and other minor infections might trigger a ... children, a new study suggests. Just five out of ... States, said Dr. Heather Fullerton, lead author of the study ... of California, San Francisco Benioff Children,s Hospital. "It seems infections ...
Breaking Medicine News(10 mins):Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3
... DETROIT, March 31 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... that all tablets of Caraco brand Digoxin, USP, 0.125 mg, ... 2009, which are not expired and are within the expiration ... consumer level. The tablets are being recalled because they may ...
... The following is a statement from Jeff Levi, PhD, Executive ... is the latest reminder of how vulnerable our food safety ... set up to respond to many modern threats to our ... and understaffed. It is encouraging that this response was so ...
... office, being advised to do what you dread exercise. ... you should exercise but probably won,t. Now imagine that ... You read that right. Eye exercises are used to treat ... clinical associate professor at the University of Houston,s College of ...
... worse with newer scheduling option, study finds , , ... same-day medical scheduling to manage their care fared no ... compared with those who made their doctor,s appointments in ... With on-demand, or open-access, scheduling, doctors, offices give patients ...
... Nephros, Inc. (OTC Bulletin Board: NEPH) announced today financial results for ... , ... Concluded pivotal U.S. clinical trial for the ... , Appointed James Scibetta Chairman ...
... Unexpected Financial, Health, and Security Risks in Exotic Locales , ... ... who continue travel spending in a down economy should prepare for ... saved on their bargain vacation. Old and new destinations offering steep ...
Cached Medicine News:Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability 3Health News:Trust for America's Health on the Recall of Certain Pistachios and the U.S. Food Safety System 2Health News:Eye exercises help patients work out vision problems, UH optometrist says 2Health News:Eye exercises help patients work out vision problems, UH optometrist says 3Health News:For Diabetics, On-Demand Care May Not Help 2Health News:Nephros Reports 2008 Fourth Quarter and Full Year Financial Results 2Health News:Nephros Reports 2008 Fourth Quarter and Full Year Financial Results 3Health News:Nephros Reports 2008 Fourth Quarter and Full Year Financial Results 4Health News:Nephros Reports 2008 Fourth Quarter and Full Year Financial Results 5Health News:Nephros Reports 2008 Fourth Quarter and Full Year Financial Results 6Health News:Nephros Reports 2008 Fourth Quarter and Full Year Financial Results 7Health News:Don't Sacrifice Your Well-being in a Discount Destination 2Health News:Don't Sacrifice Your Well-being in a Discount Destination 3
(Date:8/20/2014)... 20, 2014 The National Necrotizing Fasciitis Foundation (NNFF) ... has been successfully treated for a life threatening form of ... R. Gauto , Medical Director of Inpatient Wound Care and ... in Rancho Mirage, California . ... John Crew at Seton Hospital in ...
(Date:8/20/2014)... -- Research and Markets has announced ... Care and Closure Market (Types, Applications, End User ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... their offering. The new report ... (types, applications, end user and geography) - Size, ...
(Date:8/20/2014)... ANN ARBOR, Mich. and ... a non-profit corporation established to bring cutting-edge next-generation ... trials to cancer patients, today announced a collaboration ... molecular capabilities to characterize patient tissue samples from ... be sensitive or resistant to TESARO,s TSR-011.  This may ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... , , , , TEL ... - StemEx Study is Enrolling Patients at Cord Blood Transplant Centers in,the U.S., ... , Elbit Imaging Ltd. (NASDAQ: EMITF ) ("Elbit" ... Cell Ltd. ("Gamida Cell") through the Gamida-Teva Joint Venture (JV),announced today that the ...
... , , SAN DIEGO , ... a leading, global medical device company, today reported results from continuing ... 2009 . , "We continued to execute well during our ... Schlotterbeck , chairman and CEO of CareFusion. "Hospital capital spending made ...
Cached Medicine Technology:Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 2Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 3Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 4Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 5CareFusion Reports Second Quarter Results 2CareFusion Reports Second Quarter Results 3CareFusion Reports Second Quarter Results 4CareFusion Reports Second Quarter Results 5CareFusion Reports Second Quarter Results 6CareFusion Reports Second Quarter Results 7CareFusion Reports Second Quarter Results 8CareFusion Reports Second Quarter Results 9CareFusion Reports Second Quarter Results 10CareFusion Reports Second Quarter Results 11CareFusion Reports Second Quarter Results 12CareFusion Reports Second Quarter Results 13CareFusion Reports Second Quarter Results 14CareFusion Reports Second Quarter Results 15CareFusion Reports Second Quarter Results 16CareFusion Reports Second Quarter Results 17CareFusion Reports Second Quarter Results 18
... Biotech Captia™ Legionella pneumophila IgG/IgM ... intended for the qualitative detection ... IgM) to Legionella pneumophila (Legionella) ... patients with clinical suspicion of ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
... approach to treatment that makes ... range to 25 cm H2O, ... patients with severe OSA. BiPAP ... humidification and built-in Encore® Pro ...
... HDL into large, intermediate and small particles ... The test procedure is simple and can ... A color coded profile is generated where ... Lipoprint HDL Kit contains all reagents necessary ...
Medicine Products: